Janux Therapeutics, Inc.
HealthcareNASDAQ:JANX · NASDAQ Global Market
-$0.10 today
Vol 0.86M · Avg 1.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-11.9%
avg 5.1%
ROIC
-16.0%
avg -1051.8%
ROA
-11.3%
avg -103.6%
Analysis
ROA is currently the strongest return metric at -11.3% versus its period average of -103.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David Alan Campbell | President, Co-Founder, CEO & Director | $1.05M | — | 66 | $381,582.00 | 0.63% |
Thomas Diraimondo | Chief Scientific Officer | $653,904.00 | — | 40 | $155,825.00 | 0.26% |
William Y. Go | Chief Medical Officer | $626,400.00 | — | 50 | $154,000.00 | 0.25% |
Charles Winter | Chief Technical Officer | $590,400.00 | — | 57 | $106,321.00 | 0.17% |
Janeen Doyle | Chief Corporate & Business Development Officer | $549,029.00 | — | 48 | $75,941.00 | 0.12% |
James Pennington | General Counsel & Corporate Secretary | — | — | — | — | — |
Matt Whitmire | Vice President of Finance | — | — | — | — | — |
Maria Dobek | Vice President of Accounting | — | — | 36 | $32,270.00 | 0.05% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$1.06M
Net Sentiment
$1.06M
Net selling
Most Active
Meyer Andrew Hollman
5 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $1.06M over the last 12 months. That adds up to net selling of $1.06M. Meyer Andrew Hollman was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +51.1% (7yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +51.1% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.99B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.62B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Biohaven Ltd.
NYSE:BHVN
$1.19B
Who manages JANX?
Janux Therapeutics, Inc. (JANX) lists 8 active executives. The top listed executive is Thomas Diraimondo, Chief Scientific Officer.
Are JANX insiders buying or selling?
Recent insider activity shows net buying of $35.89M.
Explore More
Continue the stock analysis
Jump to another research area for this company.